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journal homepage: http: / /www.derm-sinica.comCORRESPONDENCEExogenous ochronosisDear Editor, recessivemetabolic disorder resulting from a deﬁciency of homoge-A 50-year-old overseas Chinese woman presented with a 5-year
history of symmetrical hyperpigmented patches on both cheeks of
the face. These facial lesions were initially diagnosed as melasma
and had been treated using laser therapy in Southeast Asia. For
the past 4 years, the patient had also applied to these sites bleaching
agents obtained from Singapore that contained 4% hydroquinone.
However, despite the treatment, the hyperpigmentationworsened.
A physical examination indicated asymptomatic, ill-deﬁned,
speckled slate-gray to brownish macules and patches on both
cheeks, zygomatic arches, lateral canthi, and the neck (Figure 1).
The remainder of the skin examination was unremarkable. The pa-
tient recalled no previous inﬂammatory dermatosis on her face. In
addition, she was otherwise healthy and denied joint, genitouri-
nary, or cardiac symptoms. She also denied having taken estrogen,
amiodarone, minocycline, or other medications. A 4-mm punch bi-
opsy was performed on the right zygomatic area. A histological ex-
amination revealed the deposition of yellow-brown, swollen,
banana-shaped ﬁbers in the upper dermis and a sparse lymphocytic
inﬁltrate (Figure 2). In contrast to the negative results of Fontana
Masson and Perls’ iron stains, methylene blue and elastic staining
highlighted these atypical ﬁbers (Figure 2). Under a tentative
diagnosis of ochronosis, another physical examination was per-
formed and the entire system was reviewed. The patient’s eyes
and urination were unremarkable and without pigmentation.
Laboratory surveys d including a complete blood count; urinary
analysis; liver, renal, and thyroid function tests; lipid proﬁles; blood
sugar; rheumatoid factor; and chest radiographs revealed no abnor-
malities. Thus, a diagnosis of exogenous ochronosis was estab-
lished. The patient was then treated using Q-switched lasers as a
trial according to the related literature.1,2 A 1 cm  1 cm area on
the left zygoma was treated using a Q-switched NdeYAG laser
(HOYA, Fremont, California, USA) at 1064 nm, 5.3 J/cm2, and a 3-
mm spot size. Simultaneously, the right zygomatic area was treated
using a Q-switched Alexandrite laser (Candela, Wayland, Massa-
chusetts, USA) at 755 nm, 8.5 J/cm2, and a 3-mm spot size. The
pigmentation of both test areas darkened after two treatments
were administered at an interval of 5 weeks. After the failure of
Q-switched lasers, CO2 laser dermabrasionwas suggested to the pa-
tient as a possibly effective treatment but she elected to go to
another country for further consultation. No further intervention
was attempted thereafter.
There are two types of ochronosis: endogenous and exogenous.
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be converted into maleylacetoacetic acid. Excessive homogentisic
acid is then deposited into many tissues, resulting in dark discolor-
ation of the skin, arthropathy, and cardiovascular complications.3
Exogenous ochronosis is conﬁned to the skin and does not
involve an underlying enzymatic defect. It manifests as asymptom-
atic blue-black macules on malar areas, temples, inferior cheeks,
and the neck.4 A typical histopathology and the absence of systemic
involvement are the diagnostic criteria.
Clinically, exogenous ochronosis appears very similar to
melasma. Other differential diagnoses include bilateral nevus of
Ota, Riehl melanosis, acquired bilateral nevus of Ota-like
macules, postinﬂammatory hyperpigmentation, and drug-inducedFigure 1 Ill-deﬁned, speckled slate-graymacules and patches on the (A) face and (B) neck.
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Figure 2 (A) Skin biopsy from the right zygomatic area shows the deposition of yellow-brown, swollen, banana-shaped ﬁbers in the upper dermis (hematoxylin and eosin stain,
40). These atypical ﬁbers are also indicated by (B) methylene blue (40) and (C) elastic staining (40).
Correspondence / Dermatologica Sinica 33 (2015) 29e3030hyperpigmentation, such asminocycline and amiodarone. A skin bi-
opsy is important and sufﬁces to offer a diagnosis. Histologically,
yellow-brown, banana-shaped ﬁbers can be observed in the upper
dermis of ochronotic lesions. They represent degenerated elastic
or collagen ﬁbers with deposits of ochronotic pigment, which can
be stained blue-black with methylene blue but not Perls’ or Fon-
tanaeMasson stains. Homogenization and swelling of collagen bun-
dles can be observed in early lesions.1,5 Sarcoid-like granulomas and
the phagocytosis of ochronotic ﬁbers by multinucleated giant cells
were reported.6 Transepidermal and transfollicular elimination of
ochronotic ﬁbers have been documented.7 Ultrastructural examina-
tions show amorphous electron-dense structures that inﬁltrate
collagen bundles or are located within the core of elastic ﬁbers.
Dermoscopic features of exogenous ochronosis have been
described. It reveals irregular brown-gray globular, annular, and
arciform structures throughout the lesion. By contrast, the dermo-
scopic features of melasma are different and are characterized by a
ﬁne brown reticular pattern on a background of a faint light brown
structureless area. Therefore, a clinicianmay use the dermoscope to
make a diagnosis; an invasive diagnostic method such as skin bi-
opsy may not be required.8
Our patient recalled using topical bleaching agents containing
4% of hydroquinone for 4 years prior to the development of the cur-
rent pigment disorder. The use of topical hydroquinone is the most
common cause of exogenous ochronosis. Topical hydroquinone is
believed to locally inhibit homogentisic acid oxidase in the skin,
resulting in the polymerization of excess homogentisic acid, and ul-
timately forming ochronotic pigment. In addition, associations with
phenol, quinine injections, resorcinol, and oral antimalarial agents
have also been indicated.9
Initially, only the prolonged use of high concentrations of hydro-
quinone for at least 6 months was thought to cause exogenous
ochronosis. However, topical application of 2% hydroquinone for
merely 3 months has also been reported to result in the develop-
ment of this disorder.9,10
The treatment of exogenous ochronosis remains challenging,
and avoidance of the inducing agent is critical. Applications of
topical retinoic acid, trichloroacetic acid, corticosteroids, and cryo-
therapy are not effective.11 The efﬁcacy of laser therapy varies.
Dermabrasion using a CO2 laser was reported to yield satisfactory
results.12 Q-switched lasers with the wavelengths absorbed by
melanin have been used in the literature with success. For example,
a case of exogenous ochronosis treated with a Q-switched ruby
laser (694 nm) showed improvement in ochronotic lesions.1 Bellew
and Alster2 reported that Q-switched Alexandrite 755-nm lasers
are effective for treating exogenous ochronosis. By contrast, the ef-
fect of intensed pulsed light therapy at 645 nmwas unsatisfactory.8Regarding the case described in this paper, the results of laser ther-
apy using twomodalities (a Q-switched Alexandrite laser at 755 nm
and a Q-switched NdeYAG laser at 1064 nm) showed unwanted re-
sults. Our case was the ﬁrst to use the 1064-nm NdeYAG laser to
treat ochronosis. It showed similar results with the Q-switched
Alexandrite laser, both of which were darker than the untreated
area. Further investigation is required to establish effective treat-
ments for exogenous ochronosis.
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